載入...
Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
BACKGROUND: We report a subgroup analysis of afatinib with respect to its efficacy, safety, and the long‐term survival of patients in a Named Patient Use program at a single institution. METHODS: We analyzed 60 patients with stage IV non‐small cell lung cancer (NSCLC) who had been treated with ≥1 li...
Na minha lista:
| 發表在: | Thorac Cancer |
|---|---|
| Main Authors: | , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
John Wiley & Sons Australia, Ltd
2021
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8107028/ https://ncbi.nlm.nih.gov/pubmed/33811467 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13957 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|